Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: Davunetide
DRUG: Placebo

Sponsor

Allon Therapeutics